State Board of Administration of Florida Retirement System Invests $328,000 in REGENXBIO Inc. (RGNX) Stock

State Board of Administration of Florida Retirement System bought a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 9,965 shares of the biotechnology company’s stock, valued at approximately $328,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Victory Capital Management Inc. lifted its position in REGENXBIO by 4.5% during the third quarter. Victory Capital Management Inc. now owns 48,529 shares of the biotechnology company’s stock valued at $1,599,000 after purchasing an additional 2,070 shares during the period. Nationwide Fund Advisors raised its position in shares of REGENXBIO by 7.4% in the third quarter. Nationwide Fund Advisors now owns 52,725 shares of the biotechnology company’s stock worth $1,737,000 after acquiring an additional 3,651 shares during the period. Ardsley Advisory Partners acquired a new position in shares of REGENXBIO in the second quarter worth about $197,000. Asymmetry Capital Management L.P. raised its position in shares of REGENXBIO by 12.2% in the second quarter. Asymmetry Capital Management L.P. now owns 13,906 shares of the biotechnology company’s stock worth $275,000 after acquiring an additional 1,508 shares during the period. Finally, California State Teachers Retirement System raised its position in shares of REGENXBIO by 22.3% in the second quarter. California State Teachers Retirement System now owns 48,775 shares of the biotechnology company’s stock worth $963,000 after acquiring an additional 8,900 shares during the period. Institutional investors own 72.09% of the company’s stock.

Shares of REGENXBIO Inc. (NASDAQ:RGNX) opened at $27.80 on Tuesday. REGENXBIO Inc. has a one year low of $16.30 and a one year high of $36.10.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.04. The business had revenue of $1.34 million during the quarter. REGENXBIO had a negative net margin of 764.06% and a negative return on equity of 39.33%. equities analysts predict that REGENXBIO Inc. will post -2.71 earnings per share for the current year.

A number of brokerages have weighed in on RGNX. BidaskClub upgraded shares of REGENXBIO from a “hold” rating to a “buy” rating in a research report on Saturday, August 12th. Zacks Investment Research upgraded shares of REGENXBIO from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research report on Saturday, August 12th. Evercore ISI began coverage on shares of REGENXBIO in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $25.00 price objective for the company. ValuEngine downgraded shares of REGENXBIO from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Finally, Chardan Capital upped their price objective on shares of REGENXBIO from $75.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $43.17.

In related news, CFO Vittal Vasista sold 5,000 shares of the company’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $33.25, for a total transaction of $166,250.00. Following the completion of the sale, the chief financial officer now owns 92,283 shares of the company’s stock, valued at approximately $3,068,409.75. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Kenneth T. Mills sold 10,000 shares of the company’s stock in a transaction dated Friday, October 20th. The shares were sold at an average price of $32.62, for a total transaction of $326,200.00. Following the sale, the insider now directly owns 98,730 shares of the company’s stock, valued at approximately $3,220,572.60. The disclosure for this sale can be found here. Insiders have sold 200,500 shares of company stock valued at $5,680,200 in the last three months. Corporate insiders own 17.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “State Board of Administration of Florida Retirement System Invests $328,000 in REGENXBIO Inc. (RGNX) Stock” was originally posted by Stock Observer and is owned by of Stock Observer. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.thestockobserver.com/2017/11/21/state-board-of-administration-of-florida-retirement-system-invests-328000-in-regenxbio-inc-rgnx-stock.html.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Institutional Ownership by Quarter for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply